Ohara Pharmaceutical Overview
- Year Founded
-
1964
- Status
-
Private
- Employees
-
468
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$69.1M
- Investors
-
3
Ohara Pharmaceutical General Information
Description
Manufacturer of prescription medicines intended to address rare and specialized medical conditions. The company develops, manufactures, and distributes pharmaceutical products including treatments for rare diseases, oncology, leukemia, liver related disorders, and selected generics, with activities covering research, clinical development, regulatory compliance, enabling hospitals, healthcare providers, and patients to access reliable medicines that support treatment continuity, medical safety, and affordability within regulated healthcare systems.
Contact Information
Website
www.ohara-ch.co.jpCorporate Office
- 36 Floor Saint Luke's Tower, 8-1 Akashi-cho
- Chuo-ku
- Tokyo, 104-6591
- Japan
Corporate Office
- 36 Floor Saint Luke's Tower, 8-1 Akashi-cho
- Chuo-ku
- Tokyo, 104-6591
- Japan
Ohara Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 30-Jun-2025 | $69.1M | Completed | Clinical Trials - Phase 3 | ||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 3 |
Ohara Pharmaceutical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class A Shares |
Ohara Pharmaceutical Patents
Ohara Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025263591-A1 | Crystalline form of oral dnmt inhibitor | Pending | 21-Jun-2024 | ||
| WO-2025142803-A1 | Pharmaceutical composition for oral administration of dnmt inhibitor | Inactive | 25-Dec-2023 | ||
| JP-2025122084-A | Levodopa sustained release formulation | Pending | 28-Jul-2022 | ||
| WO-2024024865-A1 | Levodopa sustained release formulation | Inactive | 28-Jul-2022 | ||
| JP-7719476-B2 | Cbp/catenin inhibitor treatment regimen for liver fibrosis | Active | 28-Apr-2022 |
Ohara Pharmaceutical Signals
Ohara Pharmaceutical Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| JIC Venture Growth Investments | Venture Capital | Minority | ||
| Regional Medical Revitalization Healthcare Fund Investment Business | Corporation | Minority | ||
| LINK-J | Accelerator/Incubator |
Ohara Pharmaceutical Investments (9)
Ohara Pharmaceutical’s most recent deal was a PE Growth/Expansion with MyDawa for . The deal was made on 30-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MyDawa | 30-Apr-2025 | PE Growth/Expansion | Specialty Retail | ||
| Africa Healthcare Network | 22-Nov-2023 | Later Stage VC | Clinics/Outpatient Services | ||
| Helium Health | 05-Jun-2023 | Later Stage VC | Medical Records Systems | ||
| Revital Healthcare | 28-Dec-2021 | PE Growth/Expansion | Medical Supplies | ||
| J-Pharma | 11-Aug-2021 | Later Stage VC | Drug Discovery |
Ohara Pharmaceutical FAQs
-
When was Ohara Pharmaceutical founded?
Ohara Pharmaceutical was founded in 1964.
-
Where is Ohara Pharmaceutical headquartered?
Ohara Pharmaceutical is headquartered in Tokyo, Japan.
-
What is the size of Ohara Pharmaceutical?
Ohara Pharmaceutical has 468 total employees.
-
What industry is Ohara Pharmaceutical in?
Ohara Pharmaceutical’s primary industry is Drug Discovery.
-
Is Ohara Pharmaceutical a private or public company?
Ohara Pharmaceutical is a Private company.
-
What is the current valuation of Ohara Pharmaceutical?
The current valuation of Ohara Pharmaceutical is .
-
What is Ohara Pharmaceutical’s current revenue?
The current revenue for Ohara Pharmaceutical is .
-
How much funding has Ohara Pharmaceutical raised over time?
Ohara Pharmaceutical has raised $69.1M.
-
Who are Ohara Pharmaceutical’s investors?
JIC Venture Growth Investments, Regional Medical Revitalization Healthcare Fund Investment Business, and LINK-J have invested in Ohara Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process